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Several strategies have been pursued to increase the extent of exon 7 inclusion during splicing of SMN2 (survival of
motor neuron 2) transcripts, for eventual therapeutic use in spinal muscular atrophy (SMA), a genetic neuromuscular
disease. Antisense oligonucleotides (ASOs) that target an exon or its flanking splice sites usually promote exon
skipping. Here we systematically tested a large number of ASOs with a 29-O-methoxy-ethyl ribose (MOE) backbone that
hybridize to different positions of SMN2 exon 7, and identified several that promote greater exon inclusion, others that
promote exon skipping, and still others with complex effects on the accumulation of the two alternatively spliced
products. This approach provides positional information about presumptive exonic elements or secondary structures
with positive or negative effects on exon inclusion. The ASOs are effective not only in cell-free splicing assays, but also
when transfected into cultured cells, where they affect splicing of endogenous SMN transcripts. The ASOs that promote
exon 7 inclusion increase full-length SMN protein levels, demonstrating that they do not interfere with mRNA export or
translation, despite hybridizing to an exon. Some of the ASOs we identified are sufficiently active to proceed with
experiments in SMA mouse models.
Citation: Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR (2007) Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 5(4):
e73. doi:10.1371/journal.pbio.0050073
Introduction
Spinal muscular atrophy (SMA), the most common genetic
cause of infant mortality, is an autosomal recessive neuro-
muscular disease characterized by progressive loss of a-motor
neurons in the anterior horns of the spinal cord, leading to
limb and trunk paralysis and atrophy of voluntary muscles.
Based on the severity and age of onset, SMA is clinically
subdivided into types I, II, and III (MIMs 253300, 253550, and
253400), with type I being the most severe [1]. SMA has an
incidence of approximately one in 6,000 live births, and a
carrier frequency of one in 40.
Loss of function of the survival of motor neuron 1 (SMN1)
gene is responsible for SMA [2]. Mice with homozygous SMN1
disruption display massive cell death during early embryo-
genesis [3]. SMN protein is ubiquitously expressed and is
mainly localized in the cytoplasm and in nuclear ‘‘gems’’ [4].
Multiple SMN-interacting partners have been identiﬁed,
suggesting the involvement of SMN in various cellular
processes, such as transcription, mRNA transport, and
assembly of ribonucleoprotein particles (RNPs), including
small nuclear RNPs (snRNPs), small nucleolar RNPs
(snoRNPs), and stress granules [5–8].
Humans have an extra SMN gene copy, designated SMN2.
Both SMN genes reside within a segmental duplication on
Chromosome 5q13 as inverted repeats [2]. SMN1 and SMN2
are almost identical, except for 11 nucleotide substitutions:
seven in intron 6, two in intron 7, one in coding exon 7 (a
translationally silent C to T transition, relative to SMN1), and
one in non-coding exon 8 [9]. SMN2 is a prototypical example
of alternative splicing caused by a single nucleotide sub-
stitution in the affected exon. Exon 7 is efﬁciently included in
spliced mRNA from the SMN1 gene; however, the silent C6T
transition in SMN2 exon 7, which weakens the recognition of
the upstream 39 splice site [10], results in signiﬁcant skipping
of this exon during pre-mRNA splicing. The C6T transition
abrogates a splicing factor 2/alternative splicing factor (SF2/
ASF)-dependent exonic splicing enhancer (ESE); this SF2/ASF
heptamer motif is present in SMN1 exon 7 (nucleotidesþ6 to
þ13, CAGACAA) and supersedes the inhibitory effect of
heterogeneous nuclear ribonucleoprotein (hnRNP) A1 [11–
13]. As a result, SMN2 encodes mostly the exon 7–skipped
protein isoform (SMND7), which is unstable, mislocalized, and
at best, only partially functional [14–16]. Although the small
amount of full-length SMN protein derived from SMN2 is not
sufﬁcient to fully compensate for loss of SMN1, it is essential
for viability in the absence of SMN1, and is an important
disease modiﬁer: in both SMA patients and mouse models,
there is an inverse relationship between SMN2 copy number
and disease severity [17,18]. These properties deﬁne SMN2 as
an ideal therapeutic target for potential treatment of SMA.
Antisense technology was initially employed to down-
regulate gene expression by targeting mRNA to induce its
degradation or block its translation [19]. Advances in
antisense chemistry allowed this technology to be applied as
a powerful tool to manipulate pre-mRNA splicing. Modiﬁca-
tion of the base, sugar, or phosphodiester structure of
oligonucleotides generates highly stable molecules with not
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only high afﬁnity for RNA targets, but also resistance to
various nucleases, including RNase H (which cleaves RNA in
RNA/DNA hybrids). The Kole laboratory pioneered the use of
antisense oligonucleotides (ASOs) to correct aberrant splic-
ing by targeting pre-mRNA, demonstrating both in vitro and
in vivo that ASOs can restore correct expression of a
defective b-globin gene by blocking the cryptic splice sites
generated by intronic mutations that cause b-thalassemia
[20,21]. Recently, ASO applications to redirect pre-mRNA
splicing were extended to genes with therapeutic relevance to
cancer or other diseases [22–24]. ASOs have been employed
to promote skipping of non-essential exons, so as to restore
the translational reading frame and suppress the effects of
various deletion, nonsense, and frameshifting alleles of the
dystrophin gene (DMD) [25–27]. Although it is now relatively
straightforward to block the use of speciﬁc exons by targeting
the corresponding 59 or 39 splice sites or empirically selected
sequences within the exon, it remains much more challenging
to ﬁnd suitable antisense targets for promoting exon
inclusion.
Several antisense approaches have been documented to
promote SMN2 exon 7 splicing. One approach is based on the
notion that there is a competition between the 39 splice sites
of exons 7 and 8 for pairing with the 59 splice site of exon 6
[10], so impairing the recognition of the 39 splice site of exon
8 should favor exon 7 inclusion. Increased SMN2 exon 7
inclusion and full-length SMN protein were indeed observed
in HeLa cells transfected with a modiﬁed U7 small nuclear
RNA (snRNA) complementary to the intron 7/exon 8 junction
[28]. Another approach, called TOES (targeted oligonucleo-
tide enhancer of splicing) [29], relies on bifunctional ASOs
composed of one segment complementary to exon 7 and a
non-complementary tail consisting of RNA sequences with
ESE motifs recognized by a serine/arginine-rich (SR) protein.
One such bifunctional ASO stimulated SMN2 exon 7
inclusion and led to signiﬁcant restoration of gem num-
ber—an indicator of SMN protein increase—in SMA-patient
ﬁbroblasts [30]. Moreover, an in vivo delivery system was
recently developed for expression of bifunctional ASOs in an
adeno-associated virus vector [31].
Strong intronic splicing silencers (ISSs) represent ideal
antisense targets; however, if present, they are usually
inconspicuous within large introns. An ISS in intron 6 was
identiﬁed in the context of an SMN2 minigene, and targeting
this inhibitory element with an ASO increased exon 7
inclusion in transiently transfected COS-7 cells [32]. An
intron 7 ISS, located immediately downstream of the 59 splice
site of exon 7, was recently reported; an ASO against this
silencer efﬁciently restored exon 7 inclusion of SMN2 and
increased SMN protein levels in SMA-patient–derived cells
[33].
The ESSENCE (exon-speciﬁc splicing enhancement by
small chimeric effectors) method, which was developed to
rescue disease-associated exon skipping or modulate alter-
native splicing, employs small chimeric effectors designed to
emulate SR proteins [34,35]. A synthetic ESSENCE molecule
comprises two portions: an antisense moiety complementary
to a target exon; and a minimal RS domain peptide similar to
the splicing activation domain of SR proteins. We described
several ESSENCE compounds that signiﬁcantly promote
SMN2 exon 7 inclusion in a cell-free splicing assay [34].
Interestingly, the antisense moiety alone also signiﬁcantly
stimulates exon 7 inclusion, although with approximately 8-
fold less potency compared to ESSENCE compounds,
suggesting the existence of an exonic splicing silencer (ESS)
in exon 7 [34]. This observation highlighted the possibility of
further optimization of the antisense moiety of ESSENCE
compounds to enhance their potency. Here, we used two-step
ASO walks along SMN2 exon 7 to deﬁne position-dependent
effects of ASO-binding sites. With the ﬁrst coarse whole–exon
7 walk, we identiﬁed two ASO target regions separated by a
central core sequence, and with the second high-resolution
walks, we identiﬁed optimal ASOs against each target region.
The two best ASOs strongly promoted exon 7 inclusion
during SMN2 pre-mRNA splicing in three different splicing
assays, and increased SMN protein levels in cultured cells,
including SMA type I ﬁbroblasts. Thus, appropriate ASOs
targeting a coding exon can increase protein levels by
promoting exon inclusion and not interfering with trans-
lation. Most importantly, the effective ASOs should be
suitable for studies in animals and to further optimize
bifunctional or peptide-linked ASOs for better efﬁcacy in
rescuing SMN2 splicing and full-length protein expression.
Results
ASO Walk along SMN2 Exon 7
Previously we reported that one PNA (peptide nucleic acid)
ASO complementary to positions þ7 to þ18 of SMN2 exon 7
stimulates exon 7 inclusion during splicing in vitro [34]. This
unexpected observation suggested that the ASO blocked one
or more putative ESSs—either a speciﬁc motif or a secondary
structure that impairs the recognition of exon 7. To pinpoint
the exact locations of these presumptive elements, we used a
systematic ASO walk along the entire length of SMN2 exon 7.
Oligonucleotides with a 29-O-methoxy-ethyl ribose (MOE)
phosphodiester backbone were used. This backbone modiﬁ-
cation imparts a very high afﬁnity for targeted mRNA,
resistance to both exo- and endonucleases, and does not
support cleavage of hybridized mRNA by RNase H [36,37]. We
synthesized nineMOE 15-mer ASOs complementary to the 54-
nucleotide (nt) exon 7; beginning with the ﬁrst position of the
exon, the overlapping ASOs provide coverage in 5-nt incre-
ments from 59 to 39, with a last step of 4 nt to the last position
Author Summary
Spinal muscular atrophy (SMA) is a severe genetic disease that causes
motor-neuron degeneration. SMA patients lack a functional SMN1
(survival of motor neuron 1) gene, but they possess an intact SMN2
gene, which though nearly identical to SMN1, is only partially
functional. The defect in SMN2 gene expression is at the level of
pre-mRNA splicing (skipping of exon 7), and the presence of this gene
in all SMA patients makes it an attractive target for potential therapy.
Here we have surveyed a large number of antisense oligonucleotides
(ASOs) that are complementary to different regions of exon 7 in the
SMN2 mRNA. A few of these ASOs are able to correct the pre-mRNA
splicing defect, presumably because they bind to regions of exon 7
that form RNA structures, or provide protein-binding sites, that
normally weaken the recognition of this exon by the splicing
machinery in the cell nucleus.Wedescribe optimal ASOs that promote
correct expression of SMN2 mRNA and, therefore, normal SMN
protein, in cultured cells from SMA patients. These ASOs can now be
tested in mouse models of SMA, and may be useful for SMA therapy.
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of the exon (Figure 1A, Table 1). An unrelated oligonucleo-
tide, 00–00, was used as a negative control (Table 1).
We ﬁrst evaluated these ASOs by in vitro splicing in HeLa
cell nuclear extract with a radiolabeled SMN2 minigene
transcript [11]. Although the precise extent of exon 7
inclusion varies between extracts or depending on the precise
reaction conditions, the difference between SMN1 and SMN2
is highly reproducible. We tested eight different concen-
trations of each ASO, from 1 to 400 nM, compared to no ASO.
As shown in Figure 1B, the nine ASOs had different effects on
splicing of the SMN2 pre-mRNA. Four ASOs, 01–15, 16–30,
21–35, and 26–40, strongly inhibited exon 7 inclusion; ASOs
11–25 and 31–45 slightly inhibited exon 7 inclusion; and ASO
40–54 and the control oligonucleotide 00–00 had no effect on
alternative splicing of SMN2 exon 7. Interestingly, we found
two ASOs, 06–20 and 36–50, that signiﬁcantly stimulated exon
7 inclusion in the cell-free splicing assay, starting at a
concentration of approximately 50 nM.
ASO 01–15 targets the exonic portion of the 39 splice site,
whereas ASOs 11–25, 16–30, 21–35, and 26–40 target a central
region that comprises a transformer 2 beta 1 protein
(Tra2b1)-binding motif in SMN exon 7 [38]. Both elements
are required for exon 7 inclusion, which can account for the
negative effects of these ASOs. ASO 31–45 has a 10-nt overlap
with the stimulatory ASO 36–50, yet it had a negative effect
on splicing of exon 7, suggesting that there is a motif
upstream of the ASO 36–50-binding site that is also
important for exon 7 inclusion. ASO 40–54 targets the
exonic portion of the exon 7 59 splice site; however, it is
essentially neutral. We offer two explanations for this
observation: ﬁrst, the exonic portion of this 59 splice site
deviates from the consensus sequence, and thus ASO 40–54
might not affect U1 snRNA base-pairing; second, ASO 40–54
has a strong predicted stem-loop structure (unpublished data)
and might not bind efﬁciently to its complementary
sequence. It is not surprising that ASO 06–20 had a positive
effect, because it encompasses the sequence of the antisense
PNA we reported previously [34]; however, ASO 36–50, which
is complementary to nucleotidesþ36 toþ50 of exon 7, deﬁnes
an additional region in SMN2 exon 7 that can be targeted to
increase exon 7 inclusion.
To determine whether the ASO-mediated stimulation of
exon 7 inclusion can take place in cells, we co-transfected
plasmid pCI-SMN2 with each of the nine MOE ASOs into
HEK293 cells by electroporation. At the same time, we co-
transfected plasmid pBabe Puro and selected the transfected
cells by treatment with puromycin. Two days after trans-
fection, we analyzed the transiently expressed RNA by RT-
PCR (Figure 2A). Each of the ASOs gave similar effects on
splicing of exon 7 in the minigene pre-mRNA as observed by
in vitro splicing (Figure 1B), except for two ASOs, 11–25 and
31–45. These two ASOs, especially the latter one, resulted in
robust inhibition of exon 7 inclusion in vivo, whereas only
slight effects were observed in vitro.
We next tested the effect of the exon 7 ASOs on splicing of
transcripts from the endogenous SMN genes in HEK293 cells.
This time, only the ASOs and plasmid pBabe Puro were
electroporated into the cells. The transfected cells were
puromycin-selected as above, and RNA samples were col-
lected 2-d post-transfection. After RT-PCR, we digested the
cDNA with DdeI to distinguish SMN2 mRNA from SMN1
mRNA [39,40]. As expected, the effects of these MOE ASOs on
Figure 1. Initial ASO Walk along Exon 7, Assayed by In Vitro Splicing
(A) Schematic representation of the binding sites for the nine MOE ASOs
used in the initial exon 7 walk. The position of complementarity of each
ASO along exon 7 is indicated by a horizontal line.
(B) Effect of ASOs on in vitro splicing of SMN2 minigene-derived pre-
mRNA. Each ASO was tested at the indicated concentrations, and SMN1
pre-mRNA was used as a positive control. The radiolabeled RNAs were
analyzed by denaturing PAGE and autoradiography. The diagrams on the
right indicate the mobilities of the various RNA species. The percentage
of exon 7 inclusion in each lane was calculated as described in Materials
and Methods, and is indicated below each autoradiogram. The two ASOs
that promote exon 7 inclusion are underlined.
doi:10.1371/journal.pbio.0050073.g001
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splicing of transcripts from the endogenous SMN2 gene were
very similar to those we observed with the SMN2 minigene
(Figure 2B). The only notable difference between the two
assays was in the relative efﬁcacy of the two positive ASOs,
06–20 and 36–50. ASO 06–20 was less efﬁcient in stimulating
exon 7 inclusion than ASO 36–50 in the in vitro splicing and
minigene splicing assays, but it was reproducibly more
efﬁcient than ASO 36–50 in the endogenous SMN2 splicing
assay.
On the basis of the above results obtained with the three
splicing assays, we conclude that exon 7 comprises three
distinct regions: a core sequence that is essential for exon 7
inclusion, and two ﬂanking regions that correspond to
putative ESSs. These two inhibitory regions correspond to
the binding sites for ASOs 06–20 and 36–50, and are
designated region A and region B, respectively.
High-Resolution Microwalks within Regions A and B
Having roughly delineated regions A and B as effective
antisense targets to stimulate exon 7 inclusion, we sought to
deﬁne their boundaries more precisely by identifying ASOs
with optimal sequences and lengths, and thus maximize exon
7 inclusion. To this end, we designed 39 new ASOs: 17 ASOs
of length 12, 15, or 16 nt, spanning 21 nt within or
overlapping region A (microwalk A), and 22 ASOs of length
12, 15, or 18 nt, spanning 22 nt within or overlapping region
B (microwalk B) (Figure 3A). The sequences of all 39 ASOs are
shown in Table 1. We ﬁrst screened all these MOE ASOs using
the in vitro splicing assay and a concentration of 100 nM for
each ASO.
The 15-mer ASO 07–21 was identiﬁed as the most effective
one in the case of microwalk A (Figure 3B). Its target site is
Table 1. MOE ASOs Used in the Two-Step Walks, and Their Exon
7 Targets
ASO Walk ASO Number ASO Sequence
Initial Walka 01–15 ATTTTGTCTAAAACC
06–20 TTTTGATTTTGTCTA
11–25 CTTCTTTTTGATTTT
16–30 CCTTCCTTCTTTTTG
21–35 GAGCACCTTCCTTCT
26–40 AATGTGAGCACCTTC
31–45 TAAGGAATGTGAGCA
36–40 TAATTTAAGGAATGT
40–54 TCCTTAATTTAAGGA
Microwalk of region Aa 08–22 CTTTTTGATTTTGTC
07–21 TTTTTGATTTTGTCT
05–19 TTTGATTTTGTCTAA
04–18 TTGATTTTGTCTAAA
03–17 TGATTTTGTCTAAAA
02–16 GATTTTGTCTAAAAC
05–20 TTTTGATTTTGTCTAA
12–23 TCTTTTTGATTT
11–22 CTTTTTGATTTT
10–21 TTTTTGATTTTG
09–20 TTTTGATTTTGT
08–19 TTTGATTTTGTC
07–18 TTGATTTTGTCT
06–17 TGATTTTGTCTA
05–16 GATTTTGTCTAA
04–15 ATTTTGTCTAAA
03–14 TTTTGTCTAAAA
Microwalk of region Ba 36–53 CCTTAATTTAAGGAATGT
35–52 CTTAATTTAAGGAATGTG
34–51 TTAATTTAAGGAATGTGA
33–50 TAATTTAAGGAATGTGAG
32–49 AATTTAAGGAATGTGAGC
39–53 CCTTAATTTAAGGAA
38–52 CTTAATTTAAGGAAT
37–51 TTAATTTAAGGAATG
35–49 AATTTAAGGAATGTG
34–48 ATTTAAGGAATGTGA
33–47 TTTAAGGAATGTGAG
32–46 TTAAGGAATGTGAGC
42–53 CCTTAATTTAAG
41–52 CTTAATTTAAGG
40–51 TTAATTTAAGGA
39–50 TAATTTAAGGAA
38–49 AATTTAAGGAAT
37–48 ATTTAAGGAATG
36–47 TTTAAGGAATGT
35–46 TTAAGGAATGTG
34–45 TAAGGAATGTGA
33–44 AAGGAATGTGAG
Control oligonucleotideb 00–00 TTGTATTCTATGTTT
aEach ASO designation corresponds to the 59 and 39 nucleotide numbers of the exon 7
sense sequence to which the ASO is complementary.
bThe sequence of the control ASO is unrelated to SMN2 exon 7.
doi:10.1371/journal.pbio.0050073.t001
Figure 2. In Vivo Validation of the Initial ASO Walk
Each ASO at a concentration of 10 lM and 2.5-lg pBabe Puro with or
without 5-lg pCI-SMN2 were transfected by electroporation, and
transfected cells selected with 2-lg/ml puromycin for 20 h. Two days
after transfection, cells were collected for total RNA preparation, and RT-
PCR was performed to analyze SMN2 pre-mRNA splicing patterns. The
PCR products were labeled by incorporation of a-32P-dCTP. The ASOs
that promote exon inclusion are underlined. Control 1: unrelated
oligonucleotide 00–00; control 2: buffer.
(A) The nine ASOs were co-transfected with pCI-SMN2, and the PCR
products analyzed by 8% native PAGE.
(B) The effects of the nine ASOs were analyzed with transcripts from the
endogenous SMN2 gene in HEK293 cells. RT-PCR products were digested
with DdeI to distinguish SMN1 from SMN2 by 6% native PAGE. The
percentage of exon 7 inclusion in each lane is indicated below each
autoradiogram. FL, full-length mRNA; D7, exon 7–deleted mRNA.
doi:10.1371/journal.pbio.0050073.g002
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shifted downstream by one nucleotide, relative to the target
site of the original ASO 06–20. In the presence of this new
ASO, the extent of exon 7 inclusion increased to 62%,
representing a signiﬁcant improvement over the original 15-
mer ASO 06–20, which gave 45% exon 7 inclusion in this
experiment. Microwalk B generated another improved ASO,
the 15-mer ASO 34–48, though at this concentration, it gave
only a slight improvement compared to the original ASO
(Figure 3C and unpublished data). The target site for this new
ASO is shifted upstream by two nucleotides, relative to the
target site of the original 15-mer ASO 36–50. We further
characterized the two improved high-resolution walk ASOs
by titration in the in vitro splicing assay. Concentrations
ranging from 1 to 400 nM of ASO 07–21 or 34–48 were tested
and compared with the original ASO 06–20 or 36–50
identiﬁed in the coarse walk. The splicing data and dose-
response curves are shown in Figure 4. The median effective
concentration (EC50) values for the two original ASOs 06–20
and 36–50 were 56 nM and 47 nM, respectively, whereas the
EC50 values for the improved ASOs 07–21 and 34–48 were
reduced to 16 nM and 13 nM, respectively.
The effects of the two groups of microwalk ASOs were
further examined in vivo, ﬁrst with the minigene pCI-SMN2
and then with the endogenous SMN1/2 genes, as described
above. Each ASO, at a concentration of 10 lM, with or
without the SMN2 minigene plasmid, was electroporated into
HEK293 cells (Figure 5A). ASO 07–21 stimulated exon 7
inclusion during splicing of the SMN2 minigene pre-mRNA
Figure 3. Two ASO Microwalks Assayed by In Vitro Splicing
(A) Nucleotides in white show the two microwalk regions.
(B) Seventeen new ASOs were screened in microwalk A. The original ASO (06–20) and the improved ASO (07–21) are underlined.
(C) Twenty-two new ASOs were screened in microwalk B. The original ASO (36–50) and the improved ASO (34–48) are underlined. SMN2 minigene pre-
mRNA was spliced in vitro as in Figure 1, in the presence of each ASO at a concentration of 100 nM. The percentage of exon 7 inclusion in each lane is
indicated below each autoradiogram.
doi:10.1371/journal.pbio.0050073.g003
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more effectively than ASO 06–20. As expected, ASO 07–21
also potently stimulated exon 7 inclusion during splicing of
the endogenous SMN2 pre-mRNA (Figure 5B). Similarly, ASO
34–48 robustly increased the inclusion of exon 7 for both the
SMN2 minigene and the endogenous SMN2 gene transcripts
(Figure 5C and 5D). The effects of all the antisense molecules
on exon 7 splicing were generally consistent between in vivo
minigene and endogenous gene assays. Compared to the in
vitro splicing assay, the two in vivo splicing assays appeared
more sensitive in terms of the stimulatory or inhibitory
effects on exon 7 inclusion caused by the tested ASOs. In
addition, some ASOs gave inconsistent effects between the in
vitro assay and the two in vivo assays: three ASOs in
microwalk A (08–22, 02–16, and 09–20) and three ASOs in
microwalk B (33–47, 34–45, and 33–44) all slightly promoted
exon 7 inclusion in vitro, but more or less inhibited exon 7
inclusion in vivo; ASOs 12–23, 35–52, 34–51, 33–50, and 32–
49 showed neutral or negligible effects on exon 7 inclusion in
vitro, but inhibited exon 7 inclusion in vivo to some extent;
and ﬁnally, ASO 38–49 showed no effect on exon 7 inclusion
in vitro or with the endogenous gene, but promoted exon 7
inclusion in the minigene co-transfections.
Themicrowalk data obtained from the two in vivo assays not
only veriﬁed the presence of a central core sequence, but also
established the precise boundaries between the core sequence
and regions A and B on either side of it. In microwalk A, the
target site for the improved ASO 07–21 extends to three
consecutive As of the proposed Tra2b1-recognition sequence
(AAAGAAGGA) [38], suggesting that this portion of the
Tra2b1-dependent ESE is not critical for binding of the
protein. This interpretation is consistent with the ﬁnding that
mutating the triple As to triple Us does not abrogate Tra2b1
recognition [38]. The triple As mark the 39 boundary of region
A; extending the walk farther downstream causes strong exon
7 skipping, as in the cases of ASOs 08–22, 12–23, and 11–22
(Figure 5A and 5B), presumably because of interference with
Tra2b1 binding. In microwalk B, ASOs that bind farther
upstream of the improved ASO 34–48, such as 33–47, 32–46,
and 33–44, caused a strong reduction in exon 7 inclusion
(Figure 5C and 5D). These three ASOs are complementary to
exon 7 with a 59-most boundary at þ33C and þ32G,
respectively, suggesting that this GC dinucleotide is part of
an element or structure important for exon 7 recognition.
This observation is also consistent with the in vivo effect of
ASO 31–45 in the initial exon 7 walk (Figure 2). The combined
data from the coarse- and high-resolution antisense walks
point to the existence of a core sequence in the middle of exon
7, fromþ22 toþ33, that is essential for exon 7 inclusion.
The microwalk data obtained from the two in vivo assays
are also useful for mapping both the 59 boundary of region A
Figure 4. Dose-Response Analysis with the Two Improved ASOs Using In Vitro Splicing
ASOs 07–21 (A) and 34–48 (C) were tested at the indicated concentrations. In vitro splicing was carried out as in Figure 1. The percentage of exon 7
inclusion in each lane is indicated below each autoradiogram.
(B) and (D) Sigmoidal curves were plotted to compare the dose-response effects of the high resolution–walk ASOs (A) and (C) with the initial-walk ASOs
(from Figure 1) using the data from three independent experiments. The error bars show standard deviations.
doi:10.1371/journal.pbio.0050073.g004
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and the 39 boundary of region B. In microwalk A, ASO 04–18
displayed the least stimulatory effects among the 15-mer
ASOs; other ASOs that target further upstream sequences
were either neutral or inhibitory. These results deﬁne the
boundaries of region A asþ4 toþ21. In microwalk B, the 15-
mer ASOs 39–53 and 38–52, whose 39-most complementary-
sequence boundaries are þ53G and þ52G, respectively, were
essentially neutral; all other 15-mer ASOs, except 33–47 and
32–46, which partly target the central core sequence, had
stimulatory effects. Therefore, nucleotides þ34 to þ51 deﬁne
the boundaries of region B. The results obtained with 12-mer
ASOs are generally consistent with those obtained with 15-
mer ASOs, except for ASO 04–15, which targets region A, but
was unexpectedly inhibitory with respect to exon 7 inclusion,
and ASO 09–20, which also targets region A, but was
inhibitory in the in vivo assays.
Figure 5. In Vivo Validation of the Two ASO Microwalks
The effects of the 17 microwalk A ASOs were examined with the SMN2 minigene expressed in HEK293 cells (A) or with the endogenous SMN2 gene in
HEK293 cells (B). The effects of the 22 microwalk B ASOs were examined with the SMN2 minigene expressed in HEK293 cells (C) or with the endogenous
SMN2 gene in HEK293 cells (D). The in vivo splicing assays were carried out as in Figure 2. Control 1: unrelated oligonucleotide 00–00; control 2: buffer.
The percentage of exon 7 inclusion in each lane is indicated below each autoradiogram.
doi:10.1371/journal.pbio.0050073.g005
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Dose-Response and Kinetic Analysis of ASO 07–21 and
ASO 34–48
The two high-resolution walk exon 7 ASOs were further
characterized with respect to their effects on splicing of the
endogenous SMN1/2 genes in HEK293 cells. We ﬁrst
conducted dose-response experiments with each ASO, using
a concentration range from 0.2 to 20 lM for electroporation.
Although we do not know the intracellular concentration of
each ASO after electroporation, inclusion of exon 7 in both
SMN1 and SMN2 transcripts showed a clear dependence on
the dose of each ASO (Figure 6A and 6B). For both ASOs, a
signiﬁcant increase in exon 7 inclusion was already noticeable
at a starting concentration of 0.2 lM; at 20 lM ASO, SMN2
exon 7 inclusion reached 87%–89%, compared to 86%–87%
SMN1 and 50%–51% SMN2 exon 7 inclusion in the untreated
cells. After treatment with ASO 07–21 or ASO 34–48, the
exon 7 inclusion level of the SMN1 gene transcripts rose to
93%–95%, indicating that these two ASOs affect the
Figure 6. Dose-Response and Time-Dependence Analysis with the Two Improved ASOs for Splicing of Endogenous SMN1/2 Pre-mRNAs
ASOs 07–21 (A) and 34–48 (B) were transfected into HEK293 cells, using starting concentrations from 0 to 20 lM for electroporation. Dose-response
curves for ASOs 07–21 and 34–48 were plotted on the right using the data obtained from three independent experiments. Error bars indicate standard
deviations. ASOs 07–21 (C) and 34–48 (D) at a concentration of 10 lMwere transfected into cells by electroporation. Cells were harvested daily for 5 d to
prepare total RNA for splicing analysis as in Figure 2. Exponential-decay curves were plotted on the right using the data obtained from three
independent experiments. Error bars indicate standard deviations. The percentage of SMN1 and SMN2 exon 7 inclusion in each lane is indicated below
each autoradiogram.
doi:10.1371/journal.pbio.0050073.g006
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recognition of sequence elements or secondary structures
present in transcripts from both SMN genes.
Next, we analyzed the effects of the two ASOs over time, as
a measure of their intracellular stability. We transfected
HEK293 cells by electroporation with each ASO at 10 lM
concentration, and total RNA samples from parallel trans-
fections were collected daily at 1–5 d post-transfection.
Robust effects were already apparent on the ﬁrst day and
reached a plateau by the second day (Figure 6C and 6D). The
strong effects persisted for at least 5 d, though a slight decline
of exon 7 inclusion level was observed, which might partly
reﬂect dilution of the ASOs as the cells divided.
Effect of ASO 07–21 and ASO 34–48 at the Protein Level
Both ASO 07–21 and ASO 34–48 strikingly increased the
amount of full-length mRNA expressed from the endogenous
SMN1/2 genes. However, because the ASOs might remain
associated with exon 7 in the spliced mRNA, they could
potentially interfere with mRNA export and/or translation.
Therefore, we sought to determine whether the stimulatory
effect of these ASOs on SMN1 exon 7 inclusion results in
increased full-length SMN protein. We could not accurately
determine this in HEK293 cells, because of the high levels of
identical SMN protein expressed from the SMN1 gene.
Therefore, we generated another SMN2 minigene construct,
designated pEGFP-SMN2. This minigene consists of an N-
terminal enhanced green ﬂuorescent protein (EGFP), a short
cloning-site sequence, a hemagglutinin epitope tag (HA tag),
SMN exon 6, a shortened intron 6 (same as in minigene pCI-
SMN2), exon 7, intron 7, and the 59 end of exon 8 (75 nt) at
the C-terminus (Figure 7A). When the pre-mRNA from this
minigene is spliced, it generates two mRNAs via exon
Figure 7. Effect of ASOs 07–21 and 34–48 at the mRNA and Protein Levels, Measured with Minigene Reporters
Either ASO, at a concentration of 10 or 30 lM, together with a minigene reporter plasmid, was electroporated into HEK293 cells as in Figure 2. Three
days after transfection and puromycin selection, cells were harvested to generate total RNA and protein samples.
(A) Diagram of the reporter constructs. pEGFP-SMN2D6 lacks most of exon 6, compared to pEGFP-SMN2. The alternatively spliced mRNAs are
designated E7-Incl and E7-Excl, and the corresponding protein products are P-Incl and P-Excl. The natural stop codons in exons 7 and 8 are shown.
(B) Total RNA samples from cells treated with 10 lM ASO were analyzed by radioactive RT-PCR with EGFP- and exon 8–specific primers. Controls include
the unrelated ASO 00–00, buffer only, and an SMN1 version of the reporter minigene. The percentage of the exon-7–included isoform is indicated below
each lane.
(C) The proteins expressed from the reporters were detected by Western blotting with a monoclonal antibody against the HA tag; a-tubulin was
detected with a monoclonal antibody as a loading control. Although exon-7–excluded mRNA expressed from the pEGFP-SMN2 plasmid was detected
(B), the corresponding protein was apparently unstable (C).
doi:10.1371/journal.pbio.0050073.g007
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inclusion or skipping. Translation of the exon 7–included
mRNA gives a larger protein of 308 amino acids (designated
P-Incl), comprising EGFP, seven amino acids (SGLRSRE)
derived from the cloning site, the HA tag, and exons 6 and 7
of SMN. The exon 7–skipped mRNA is translated into a
smaller protein of 296 amino acids (designated P-Excl),
comprising EGFP, SGLRSRE, the HA tag, exon 6, and four
amino acids (EMLA) from exon 8 (Figure 7A). Both proteins
can be detected with anti-HA antibody. Before proceeding to
the protein-level analysis, we ﬁrst veriﬁed the increase in
exon 7 inclusion for the minigene pEGFP-SMN2 after
electroporation with ASO 07–21 or 34–48. Compared with
the endogenous SMN2 gene, minigene pEGFP-SMN2 favors
the exon 7–skipped mRNA isoform. The extent of exon 7
inclusion was about 28% without any treatment; however,
after treatment with 10 lM ASO 07–21 or 34–48, exon 7
inclusion rose to 74% or 85%, respectively (Figure 7B).
Protein samples were generated 3 d after the cells were co-
transfected via electroporation with the minigene construct
and either ASO at 10 or 30 lM concentration. Surprisingly,
using mouse monoclonal anti-HA antibody, we only detected
the exon-included protein product, P-Incl, with an apparent
mass of approximately 38 kDa (Figure 7C). The effects of both
ASOs were dose dependent, and after the treatment with 30
lM ASO, P-Incl reached almost the same level as observed
with the SMN1 minigene.
We were not able to detect any P-Excl protein produced
from the SMN2 D7 mRNA transcript; we believe this is due to
protein instability. SMND7, the unstable protein isoform
derived from the SMN1/2 genes, and P-Excl share the same C-
terminus, corresponding to the peptide coded by exon 6 plus
four amino acids derived from exon 8; it is possible that these
sequences, when present close to the C-terminus, induce
degradation of the protein. To overcome this problem, we
constructed another SMN2 minigene, pEGFP-SMN2D6; this
construct is similar to pEGFP-SMN2, but lacks most of exon 6,
except for the last 9 nt, so as to maintain an intact natural 59
splice site (Figure 7A). This minigene encodes two protein
isoforms: the exon 7–included one (P-InclD6; 274 amino
acids) and the exon 7–excluded one (P-ExclD6; 262 amino
acids). Using this minigene, we again tested ASO 07–21 or 34–
48 in HEK293 cells; signiﬁcant increases in both exon 7–
included mRNA and protein were observed (Figure 7B and
7C). This time, using anti-HA antibody, we detected two
polypeptides from pEGFP-SMN2D6, with sizes of about 32
kDa and 30 kDa, and with the latter giving a stronger signal.
After treatment with the ASOs, the P-ExclD6 band disap-
peared, whereas the P-InclD6 band became considerably
stronger and comparable in intensity to the SMN1 minigene
product. To control for sample loading differences, the same
blots were reprobed with anti–a-tubulin monoclonal anti-
body. These results clearly demonstrate that ASOs targeting a
coding exon are able to promote exon inclusion at the mRNA
level, and the resulting mRNA can be translated into protein.
Effects of ASO 07–21 and ASO 34–48 in SMA-Patient
Fibroblast Cells
To test whether the in vivo results in human HEK293 cells
can be extended to SMA-patient cells, SMA type I 3813
ﬁbroblasts were transfected with either ASO at 100 nM
concentration using Lipofectin; this method of delivery was
chosen because it was more efﬁcient than electroporation
with these primary ﬁbroblast cells, consistently giving
approximately 50% transfection efﬁciency with an EGFP
plasmid (unpublished data). At 48 h after transfection, the
cells were harvested to prepare mRNA and protein samples.
The 3813 cells treated with the control ASO 00–00 or buffer
alone gave 31% exon 7 inclusion. After treatment with ASO
07–21 or 34–48, the apparent level of exon 7 inclusion
increased to 58% and 61%, respectively (Figure 8A, left);
based on the standard deviations (unpublished data; n ¼ 3),
this corresponds to a 1.9 6 0.04 fold increase for ASO 07–21,
and a 2.0 6 0.04 fold increase for ASO 34–48, relative to the
treatment with the control ASO 00–00. The increase in the
percentage of exon 7 inclusion could potentially reﬂect
reduced exon skipping alone, without the desirable concom-
itant increase in exon inclusion. To rule out this possibility,
we used GAPDH mRNA as a loading control, and calculated
the ratio of SMN full-length mRNA to GAPDH mRNA,
normalized to that observed with the control ASO 00–00
(Figure 8A, right). The ratio increased by approximately 1.6-
fold in ASO 07–21-treated cells and approximately 1.8-fold in
ASO 34–48-treated cells. To detect changes at the protein
level, we used a-tubulin as a loading control. The normalized
ratio signiﬁcantly increased by approximately 1.8-fold and
approximately 2.1-fold in ASO 07–21- and ASO 34–48-
treated samples, respectively, compared to ASO 00–00
(Figure 8B). Assuming a delivery efﬁciency of approximately
50%, the actual effects should be approximately 2-fold
greater in the cells that took up the ASOs.
Gems are nuclear bodies in which SMN protein accumu-
lates [4]. A correlation between the number of gems in
patient-derived ﬁbroblasts and SMA clinical severity has been
demonstrated [41]. To assess the effects of ASOs 07–21 and
34–48 on nuclear gem counts, we used indirect immuno-
ﬂuorescence with an anti-SMN monoclonal antibody, after
transfection of 3813 cells with either ASO. The cells treated
with the unrelated control oligonucleotide contained an
average of 10 gems per 100 cells; however, when the cells were
treated with ASO 07–21 or 34–48, the average gem number
increased to 26 or 31 per 100 cells, respectively. The carrier
3814 ﬁbroblast cells had approximately 50 gems per 100 cells
(Figure 8C–8E). In addition, after treatment with ASO 07–21
or 34–48, the number of cells containing multiple gems
increased, and the number of cells containing no gems
decreased. These results conﬁrm that ASOs 07–21 and 34–48
signiﬁcantly promote full-length SMN protein expression.
Discussion
Multiple strategies aimed at correcting exon 7 splicing of
SMN2, a modifying gene for SMA, have been investigated.
Mechanistic studies to understand how SMN2 exon 7 is
alternatively spliced led to the discovery of several cis-
elements and trans-acting factors that can be targeted to
stimulate exon 7 inclusion [42]. A number of drugs, including
synthetic compounds that can modify SMN2 splicing, have
been identiﬁed using cell-based high-throughput drug
screening [42]. On the basis of the current knowledge of
splicing mechanisms, we and others have employed antisense-
based technologies to stimulate exon 7 inclusion. In recent
years, a growing number of studies have demonstrated that
MOE-modiﬁed ASOs (with a phosphodiester or a phosphor-
othioate backbone) and antisense PNAs can be valuable tools,
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Figure 8. Effect of ASOs 07–21 and 34–48 in SMA Type I Patient 3813 Fibroblasts
Endogenous SMN2 mRNA, SMN protein levels, and gem number were analyzed after each ASO at a concentration of 100 nM was transfected into
patient fibroblasts using Lipofectin. Two days later, RNA or protein samples were collected, or indirect immunofluorescence microscopy was carried out.
Carrier 3814 fibroblasts were used as a positive control, and ASO 00–00 and buffer treatments were used as negative controls.
(A) SMN2 mRNA was analyzed by radioactive RT-PCR, using GAPDH mRNA as a loading control. The percent of SMN2 exon 7 inclusion in each lane is
shown below the autoradiogram.
(B) SMN protein was detected by Western blotting, and the same blot was re-probed with antibody against a-tubulin as a protein-loading control. The
histograms on the right of (A) or (B) show the corresponding quantitation from three independent experiments; the ratios are normalized to that
observed with the buffer control, and error bars show the standard deviations.
(C) Effect of ASOs 07–21 and 34–48 on nuclear gems. Nuclei were counterstained with DAPI. Examples of treated cells with two or more gems are shown.
(D and E) Both the total number of gems per 100 cells (D) and the number of cells with multiple gems (E) significantly increased after treatment with
ASOs 07–21 or 34–48.
doi:10.1371/journal.pbio.0050073.g008
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not only for dissecting gene function, but also for clinical
applications [19]. Our previous work showed that ESSENCE
compounds have the potential to treat diseases caused by
exon skipping resulting from the loss of ESEs in mutant
genes, including SMN2 [34]. A critical parameter in ESSENCE
effectiveness is the selection of the optimal binding site along
a target exon. In principle, the best target sequences are those
that comprise negative exonic splicing signals or secondary
structures, such as ESSs.
In this study, we systematically analyzed SMN2 exon 7 with
a large number of MOE ASOs to identify putative ESSs. We
employed a two-step ASO walk method, with an initial coarse
ASO walk in 5-nt steps along the entire exon, followed by
high-resolution single-nucleotide walks within the regions
identiﬁed in the ﬁrst step. With the ﬁrst-step walk, we
identiﬁed two ASO targets of potential therapeutic impor-
tance. The second-step microwalks optimized the ASOs and
deﬁned the apparent boundaries of the two ESS-containing
regions. Using three independent splicing assays, we identi-
ﬁed two potent ASOs that have signiﬁcant therapeutic
potential for SMA treatment. Our data also suggest that the
two-step ASO walk is a powerful general method that can be
used for screening inhibitory or stimulatory splicing regions
present in the target exon(s) and the surrounding intron
sequences of any gene.
Our data revealed an essential core sequence in the center
of the 54-nt exon 7 from þ22 to þ33 (GAAGGAAGGTGC),
which is surrounded by two separate inhibitory regions (A
and B) containing negative splicing signals, with region A
extending close to the upstream 39 splice site (þ4 toþ21) and
region B extending close to the downstream 59 splice site (þ34
to þ51) (Figure 9). Blocking any part of the central core
sequence promoted efﬁcient skipping of exon 7, whereas
blocking either of the two inhibitory regions promoted exon
7 inclusion. The 59 portion of the central core sequence
comprises a previously identiﬁed Tra2b1-binding motif
(GAAGGA) [38]; the 39 part (AGGTGC) may represent
another cis-acting element that is also crucial for exon 7
recognition. A relatively long conserved sequence in the
middle of exon 7, surrounded by two short inhibitory
sequences, was previously identiﬁed by an iterative in vitro
selection method [43]. Through an analysis of mutability,
three segmental sequences with negative or positive cis-acting
elements were inferred: the most conserved residues are
located in the middle and form a conserved tract (þ16 toþ44),
whereas the highly mutable upstream nucleotides form an
inhibitory region (þ3 to þ15), and seven highly mutable
downstream nucleotides (þ45 to þ51) form another negative
element [43]. Our data sharpen the boundaries for these three
segments, as veriﬁed by three different splicing assays and
several ASOs, particularly the two most effective ASOs, 07–21
and 34–48. The target sequence of the 15-mer ASO 07–21
overlaps by six nucleotides with the previously reported
conserved tract, and 11 out of 15 target nucleotides of ASO
34–48 are part of this conserved track. Nucleotides A36 and
C37, which fall within the inhibitory region B, have been
suggested to be part of a stimulatory motif, as the double
mutation A36U/C37U abolishes exon 7 inclusion in the SMN1
gene [43]. However, the double mutation might create a
stronger inhibitory motif, or strengthen a secondary RNA
structure that impairs exon 7 recognition.
We searched exon 7 for putative ESSs with the Web servers
PESX (http://cubweb.biology.columbia.edu/pesx) and ACES-
CAN2 (http://genes.mit.edu/acescan2/index.html). PESX found
no ESS motifs, whereas ACESCAN2 found three putative ESS
motifs: GGTTTT (þ1 toþ6), TTTTAG (þ3 toþ8) and TTCCTT
(þ39 to þ44). The ﬁrst two motifs partially overlap with the
inhibitory region A, and the last motif resides within the
inhibitory region B, so these motifs might contribute to the
inhibitory properties of regions A and B.
We note that both optimized ASOs are 15-mers, whereas all
ﬁve of the 18-mer ASOs (36–53, 35–52, 34–51, 33–50, and 32–
49) displayed more or less inhibitory effects on SMN2 exon 7
inclusion. The longer 18-mer ASOs are likely to overlap two
or more binding sites, resulting in complex effects. The
strong inhibitory effect of ASO 32–49 and the relatively weak
inhibitory effect of ASO 33–50 might be explained by their
interference with the positive regulation conferred by the
essential core sequence, because the 59-most boundary
nucleotide of their target sequence is 33G and 34C,
respectively. The other three ASOs, whose target sequences
lie next to the exon–intron junction, might interfere with
recognition of the 59 splice site.
A small fraction of the ASOs had inconsistent effects on
exon 7 splicing in the different splicing assays. One type of
inconsistency occurred between the minigene splicing assays
(both in vitro and in vivo) and the endogenous gene assay.
The other type of inconsistency occurred between the in vitro
splicing assay and the in vivo splicing assays. The ﬁrst type of
inconsistency may reﬂect the differences in the pre-mRNA
substrates, although SMN2 exon 7 was identical in all the
assays. In both the in vitro splicing assay and the in vivo
Figure 9. Schematic Diagram of the In Vivo Effects of All Tested ASOs on Exon 7 Inclusion
An essential core sequence (in bold) surrounded by two inhibitory regions, A and B (boxed), in SMN2 exon 7. Horizontal bars represent ASOs with
stimulatory effects (green), inhibitory effects (red), or neutral effects (blue). The thicker the bars, the stronger the effects. Tra2b1 and another putative
activator are shown bound to the central core region.
doi:10.1371/journal.pbio.0050073.g009
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minigene splicing assay, a small minigene was used. Higher-
order structure differences between the small minigene pre-
mRNA and the much larger endogenous pre-mRNA might
affect the accessibility of some ASOs to their target sequences
in exon 7, resulting in splicing differences. The second type of
inconsistency might reﬂect differences in the splicing-
reaction environments between the cell-free splicing assay
and the cell-based splicing assays, even though in general, the
in vitro splicing reactions accurately reproduce cellular
splicing events. For example, it is possible that the effects of
some ASOs are more sensitive to changes in the concen-
tration of certain splicing factors resulting from the nuclear
extraction procedure. Another possibility is that the discrep-
ancies result from kinetic differences and the coupling
between transcription and mRNA processing that normally
occurs in vivo, but not in standard in vitro splicing reactions
[44]; moreover, transcription from different promoters—as
in the minigene and the endogenous gene—can also affect
use of alternative cassette exons in vivo [45].
Why ASOs 07–21 and 34–48 are more effective than the
original ones, which bind to their target sequences only one or
two nucleotides upstream or downstream, is currently under
investigation. Because the ASOs have the same lengths and the
same or similar G/C contents, annealing kinetics is probably
not the cause, assuming equal accessibility to their target sites
in exon 7. Two possible explanations of the effects of ASOs 07–
21 and 34–48 are that they precisely block one ormore splicing
silencers, or efﬁciently disrupt an inhibitory RNA secondary
structure. It has been reported that hnRNP A1 can inhibit
SMN2 and SMN1 exon 7 inclusion [12,13]. In region A of SMN2,
SF2/ASFpresumably fails to block the cooperative propagation
of hnRNPA1, due to the loss of an SF2/ASFmotif caused by the
C6T transition [13]. ASO 07–21 binds a 15-nt sequence that
spans the mutant SF2/ASF motif; therefore, it is reasonable to
assume that one of the roles played byASO 07–21 is similar to a
proposed function of SF2/ASF in SMN1 exon 7, i.e., blocking
the propagation of hnRNP A1. ASO 07–21 might also block
other inhibitory motifs residing in region A, for which an
extended inhibitory context has been proposed [46]. We have
unexpectedly observed in microwalk A that the 12-mer ASO
04–15 inhibited exon 7 inclusion; ASO 09–20 was likewise
inhibitory, at least in vivo. These results suggest that the
inhibitory effect of region A is the result of interplay among
multiple trans-acting factors. It is likely that ASOs 04–15 and
09–20 can effectively block an undeﬁned weak stimulatory
signal, but cannot efﬁciently block the propagation of hnRNP
A1 and possibly other repressors. A terminal-stem loop has
been predicted in the less-studied region B, extending to two
intron 7 nucleotides [47]. Though it is possible that the
inhibitory property of region B is attributable to the proposed
RNA secondary structure itself, other possibilities cannot be
ruled out, including the existence of one or more splicing
repressors that recognize a speciﬁc motif or RNA structure.
Additional experimental studies will be required to elucidate
the precise splicing-stimulatory mechanism of ASO 34–48.
We cannot exclude the possibility that the stimulatory
ASOs act in part by stabilizing the pre-mRNAs and/or mRNAs
to which they hybridize. Because only some of the exon 7
ASOs stimulate exon 7 inclusion, such a stabilization effect
would presumably involve masking of speciﬁc instability
elements. However, the effect of the ASOs is primarily, if not
exclusively, at the level of splicing, because an effect at the
level of mRNA half-life should result in the same propor-
tional increase in SMN1 and SMN2 full-length mRNAs, yet the
effects on SMN1 were much smaller, consistent with a switch
in alternative splicing from the low basal level of exon 7–
skipped mRNA. In addition, we did not observe any ASO-
mediated stabilization of the labeled pre-mRNA in the in
vitro splicing experiments.
We used three different assays to demonstrate that the
ASOs that promote exon inclusion are compatible with
synthesis of full-length SMN protein, indicating that they do
not block mRNA export or translation. First, we showed that
ASOs 07–21 and 34–48 promote efﬁcient expression of
reporter proteins corresponding to exon 7 inclusion in
HEK293 cells. Second, we showed that the same ASOs
promote expression of full-length SMN protein in primary
ﬁbroblasts from a type I SMA patient; though signiﬁcant, this
effect appears subtle because of the relatively low trans-
fection efﬁciency with these cells. Finally, we showed that the
same ASOs promote an increase in the number of nuclear
gems detected with anti-SMN antibody in the patient
ﬁbroblasts; this single-cell immunoﬂuorescence assay obviates
the problem of transfection efﬁciency and provides an
indirect readout for SMN protein levels [4,41].
Our initial goal in this study was to deﬁne optimal
antisense targets to maximize ESSENCE effectiveness. How-
ever, our optimized antisense targets should also be useful
with bifunctional ASOs [30,31]. The antisense portions of the
bifunctional ASOs used in two earlier studies were not
optimized. The ﬁrst study used a 15-mer ASO targeting the
exon 7 sequenceþ2 toþ16 [30], i.e., the same target sequence
as that of our ASO 02–16. However, we found that this ASO
had a slightly negative effect on exon 7 inclusion in vivo with
both the SMN2 minigene and the endogenous SMN2 gene,
though it had a slightly stimulatory effect on splicing in vitro
(Figures 3B, 5A, and 5B). ASO 02–16 was one of few ASOs that
gave inconsistent effects among the different splicing assays
we used. The second study used a 20-mer ASO targeting the
exon 7 sequence þ6 to þ25 [31], which partially overlaps the
central core sequence that is essential for exon 7 inclusion.
On the basis of our results, we predict that more-effective
bifunctional ASOs targeting exon 7 can be designed, using
the ASO 07–21 or 34–48 sequences as the antisense moiety.
Although we expect that even more-potent effectors can be
designed by attaching ASOs 07–21 or 34–48 to activation-
domain peptides or SR protein–binding sites—as in the
ESSENCE [34] and TOES [29] methods—these ASOs appear
to be sufﬁciently effective on their own to be tested in animal
models of SMA. ASOs with the same chemistry were recently
demonstrated to be active modulators of splicing in mice [48].
More generally, the antisense walk strategy described here
should be applicable to identifying exon-targeting ASOs that
modulate alternative splicing of normal or mutant genes. At
the same time, these ASOs can facilitate the identiﬁcation of
important cis-regulatory sequences that can be further
investigated to elucidate splicing mechanisms, and to identify
trans-acting factors that may be useful molecular targets for
disease therapy.
Materials and Methods
Oligonucleotide synthesis. Synthesis and puriﬁcation of chimeric
29-O-methoxyethyl–modiﬁed oligonucleotides with a phosphodiester
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backbone were performed using an Applied Biosystems 380B
automated DNA synthesizer (Applied Biosystems, Foster City,
California, United States) as described previously [49]. The oligonu-
cleotides were dissolved in water. The sequences of all the
oligonucleotides are indicated in Table I.
Constructs. SMN minigene constructs used for both the in vitro
splicing assay and the in vivo minigene splicing assay in HEK293 cells
were pCI-SMN1 and pCI-SMN2, which are derivatives of
pCISMNxD6-WT and pCISMNxD6-C6T, respectively [11,50]. The
SMN minigenes comprise the 111-nt–long exon 6, a 200-nt shortened
intron 6, the 54-nt exon 7, the 444-nt intron 7, the ﬁrst 75 nt of exon
8, and a consensus 59 splice site (CAGGTAAGTACTT) to promote
exon deﬁnition in vitro. We ampliﬁed the minigenes with primer set
T7-F2 (59-TAC TTA ATA CGA CTC ACT ATA GGC TAG CCT CG-39)
and SMN8-75-59R-SalI-NotI (59-GAA GCG GCC GCG TCG ACA AGT
ACT TAC CTG TAA CGC TTC-39), and inserted them into vector
pCI-neo (Promega, Madison, Wisconsin, United States) using XhoI
and NotI. Two restriction sites, SalI and NotI, were included in the
reverse primer. Four minigene constructs were used for protein
expression: constructs pEGFP-SMN2 and pEGFP-SMN1 have the
same minigenes as in pCI-SMN2 and pCI-SMN1, but without the
consensus 59 splice site. Minigene inserts were ampliﬁed with primer
set Xho-HA-E6-F (59-GAT CTC GAG AGT ACC CAT ACG ACG TAC
CAG ATT ACG CTA TAA TTC CCC CAC CAC CTC CC-39) and Pr-
E8–75-BamH-R (59-CGG GAT CCT AAC GCT TCA CAT TCC AGA
TC-39), digested with XhoI and BamHI and subcloned into the XhoI
and BamHI sites in pEGFP-C1 (Clontech, Mountain View, California,
United States). Constructs pEGFP-SMN2D6 and pEGFP-SMN1D6 are
similar to pEGFP-SMN2 and pEGFP-SMN1, but most of exon 6 was
deleted, with only the last nine nucleotides retained to keep the
natural context of the 59 splice site of exon 6. Minigene inserts were
ampliﬁed with Pr-HA-I6-Xho-F (59-ATC TCG AGA GTA CCC ATA
CGA CGT ACC AGA TTA CGC TTA TTA TAT GGT AAG TAA TCA
CTC-39) and Pr-E8–75-BamH-R, and were subcloned into XhoI and
BamHI double-digested pEGFP-C1. One copy of the HA epitope tag
sequence was included in primers Xho-HA-E6-F and Pr-HA-I6-Xho-
F, so that all protein products expressed from the four EGFP-fused
minigene constructs have an N-terminal HA epitope tag and can be
detected with anti-HA antibody.
In vitro splicing. To generate in vitro splicing substrates, we
linearized plasmids pCI-SMN1 and pCI-SMN2 with SalI, and tran-
scribed them with T7 RNA polymerase (Promega) in the presence of
a-32P-UTP and 7MeGpppG cap analog [11,51]. Substrates were
puriﬁed by denaturing polyacrylamide gels and spliced in HeLa cell
nuclear extract, as described [52]. We incubated 8 fmol of transcript
in 10-ll splicing reactions containing 3 ll of nuclear extract and 1.6
mM MgCl2. After incubation at 30 8C for 4 h, we extracted the RNA
and analyzed it on 8% denaturing polyacrylamide gels, followed by
autoradiography and phosphorimage analysis with an Image Reader
FLA-5100 (FujiFilm Medical Systems, Stamford, Connecticut, United
States). We calculated exon 7 inclusion as a percentage of the total
amount of spliced mRNA, i.e., included mRNA 3 100/(included
mRNAþ skipped mRNA). The signal intensity of each mRNA isoform
band was normalized according to its U content.
Cell culture and transfection. HEK293 cells, SMA type I homo-
zygous and carrier ﬁbroblasts (3813 and 3814; Coriell Cell Reposito-
ries, Camden, New Jersey, United States) were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Invitrogen, Carlsbad, California,
United States) containing 10% (v/v) fetal bovine serum and anti-
biotics (100-U/ml penicillin G and 100-lg/ml streptomycin). For
transfection of MOE oligonucleotides and plasmids into HEK293
cells, electroporation was used, followed by puromycin selection
(Figures 2 and 5–7). Brieﬂy, 90 ll of freshly-prepared cells (13107/ml)
suspended in Opti-MEM medium was mixed with 10 ll of ASO/DNA
mixture in a 1-mm cuvette. A total of 2.5 lg of the plasmid pBabe
Puro [53] was included in the ASO/DNAmixture for selection. For the
in vivo minigene splicing assay and the minigene protein assays, 5 lg
of each minigene plasmid was used. For electroporation, 80 volts and
500 lF were applied with a Gene Pulser II apparatus (Bio-Rad,
Hercules, California, United States). Shocked cells were then cultured
in 60-mm dishes in normal medium. Untransfected cells were killed
by treatment with 2-lg/ml puromycin for 20 h. For transfection of
MOE oligonucleotides into 3813 cells, Lipofectin (Invitrogen) was
used according to the manufacturer’s instructions.
RT-PCR. Total RNA was isolated with Trizol reagent (Invitrogen),
and 2 lg of each RNA sample was used per 20-ll reaction for ﬁrst-
strand cDNA synthesis with Oligo-dT and Super Script II reverse
transcriptase (Invitrogen). Splicing products were ampliﬁed semi-
quantitatively using 22 PCR cycles (94 8C for 30 s, 55 8C for 30 s, and
72 8C for 36 s). Primer set T7-F2 (see above) and E8–75þ59R (59-AAG
TAC TTA CCT GTA ACG CTT CAC ATT CCA GAT CTG TC-39) was
used to amplify minigene pCI-SMN2 transcripts. Primer set EGFP-C
(59-CAT GGT CCT GCT GGA GTT CGT G-39) and Pr-E8–75-BamH-R
was used to amplify transcripts from plasmids pEGFP-SMN1, pEGFP-
SMN2, pEGFP-SMN1D6, and pEGFP-SMN2D6. Primer set E3-F (59-
ACT TTC CCC AAT CTG TGA AGT A-39) and E8-R (59-CAT TTA
GTG CTG CTC TAT GCC AGC-3) was used to amplify endogenous
SMN2 transcripts in 3813 cells; the GAPDH mRNA in 3813 cells was
used as an internal control, and was ampliﬁed with primers GAPDH-
F (59-AAG GTG AAG GTC GGA GTC AAC GG-39) and GAPDH-R (59-
CCA CTT GAT TTT GGA GGG ATC TC-39). Primer set E6-F (59-ATA
ATT CCC CCA CCA CCT CCC-39) and E8–467 (59-TTG CCA CAT
ACG CCT CAC ATA C-39) was used to amplify endogenous SMN1/2
transcripts in HEK293 cells, and the PCR products were then digested
with DdeI to distinguish their origin (SMN1 or SMN2). All PCR
products were labeled with a-32P-dCTP and separated on 6% or 8%
native polyacrylamide gels. The extent of exon 7 inclusion was
calculated as above, and the signal intensity of each cDNA band was
normalized according to its GþC content.
Plotting dose-response curves and kinetic curves. All curves were
plotted with Prism software (Graphpad Software, http://www.
graphpad.com). To compare the effects of ASOs 07–21, 34–48, 06–
20, and 36–50 on exon 7 inclusion in vitro, sigmoidal curve-ﬁtting was
used, with X values plotted on a logarithmic scale. The EC50 value of
each ASO was calculated by the software. Sigmoidal curves were also
plotted for the effects of ASOs 07–21 and 34–48, respectively, on
endogenous SMN genes in HEK293 cells. The time-course analysis of
ASOs 07–21 and 34–48 in HEK293 cells was plotted using
exponential-decay curve-ﬁtting.
Western blotting. Two or 3 d after transfection, HEK293, 3813, or
3814 cells were harvested and lysed with lysis buffer (50 mM Tris, [pH
7.6], 150 mM NaCl, 2 mM EDTA, 1.0% Nonidet P-40, 1 mM PMSF),
supplemented with protease inhibitor cocktail (Roche Applied
Science, Indianapolis, Indiana, United States). Protein samples were
separated by SDS-PAGE (sodium dodecyl sulfate -polyacrylamide gel
electrophoresis) and transferred to nylon membranes. The blots were
probed with monoclonal mouse anti-SMN (BD Transduction Labo-
ratories; BD Biosciences, San Jose, California, United States),
monoclonal mouse anti-HA (HA.11; BAbCO, Richmond, California,
United States), or monoclonal mouse anti–a-tubulin (Sigma, St. Louis,
Missouri, United States) antibody, followed by secondary goat anti-
mouse antibody labeled with yellow-ﬂuorescent Alexa Fluor 532 dye
(Molecular Probes/Invitrogen). The signal was detected with an Image
Reader FLA-5100 (FujiFilm Medical Systems).
Immunoﬂuorescence and gem counting. The 3813 and 3814
ﬁbroblasts were plated on coverslips and grown in DMEM. After
overnight growth, the cells were transfected with 100 nM oligonu-
cleotides. At 48 h post-transfection, the cells were washed with
phosphate-buffered saline (PBS) and ﬁxed with 3.7% paraformalde-
hyde in PBS for 20 min. After washing with PBS, the cells were
permeabilized in 0.1% Triton X-100 in PBS for 3 min, blocked for 30
min in blocking buffer (5% goat serum, 3% IgG-free bovine serum
albumin [BSA]), and incubated for 3 h in blocking buffer containing
mouse monoclonal anti-SMN antibody. The cells were then washed
three times with PBS and incubated for 2 h in blocking buffer
containing goat anti-mouse secondary antibody Alexa Fluor 594
(Molecular Probes/Invitrogen). The cells were again washed with PBS
three more times, and coverslips were mounted with Prolong Gold
mounting solution containing DAPI (Molecular Probes/Invitrogen)
for nuclear staining. Cells were analyzed using an Axioplan 2i
ﬂuorescence microscope (Carl Zeiss, Thornwood, New York, United
States) equipped with Chroma ﬁlters (Chroma Technology, Rock-
ingham, Vermont, United States). OpenLab software (Improvision,
http://www.improvision.com) was used to collect digital images from a
CCD camera (Hamamatsu, Bridgewater, New Jersey, United States).
To count gems, ﬁrst a ﬁeld was randomly selected using the DAPI
channel, the cell number was determined based on the DAPI
counterstaining, and then the gems were counted in the red channel.
At least three different ﬁelds were counted, and each ﬁeld contained
more than 40 cells.
Supporting Information
Accession Numbers
The UniProt (http://www.pir.uniprot.org) accession number for SMN
is Q16637–1. The Entrez Gene (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db¼gene) GeneID numbers for the genes discussed in the
paper are SMN1 (6606) and SMN2 (6607).
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